TC
ACOR

TFS Capital’s Acorda Therapeutics ACOR Stock Holding History

TFS Capital’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-379
Closed -$897K – 418
2017
Q2 		$897K Buy
379
+13
+4% +$25.8K 0.35% 71
2017
Q1 		$923K Buy
+366
New +$1.05M 0.3% 110
2016
Q3 		– Sell
-219
Closed -$671K – 1046
2016
Q2 		$671K Buy
219
+130
+146% +$423K 0.12% 287
2016
Q1 		$282K Buy
+89
New +$369K 0.04% 668
2015
Q4 		– Sell
-124
Closed -$395K – 950
2015
Q3 		$395K Sell
124
-312
-72% -$1.21M 0.04% 598
2015
Q2 		$1.75M Sell
436
-66
-13% -$255K 0.17% 186
2015
Q1 		$2M Sell
502
-414
-45% -$1.9M 0.2% 137
2014
Q4 		$4.49M Buy
916
+185
+25% +$794K 0.43% 26
2014
Q3 		$2.97M Buy
731
+457
+167% +$1.71M 0.26% 94
2014
Q2 		$1.11M Buy
274
+169
+161% +$689K 0.09% 371
2014
Q1 		$479K Sell
105
-143
-58% -$578K 0.03% 748
2013
Q4 		$869K Buy
+248
New +$967K 0.04% 606
2013
Q3 		– Sell
-213
Closed -$843K – 1669
2013
Q2 		$843K Buy
+213
New +$877K 0.04% 672

Other funds holding ACOR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

TFS Capital's ACOR Position: Q3 2017 in Review

TFS Capital sold out of Acorda Therapeutics (ACOR) in Q3 2017, closing a stake of 379 shares — an estimated $897K sold.

TFS Capital first reported a position in ACOR in Q2 2013 and held it in 13 quarters. The position peaked at $4.49M in Q4 2014. 152 funds tracked by Wall St. Rank hold ACOR as of Q3 2017.

  • TFS Capital reported no remaining Acorda Therapeutics position as of Q3 2017 after selling out during the quarter.
  • TFS Capital sold 379 Acorda Therapeutics shares in Q3 2017, an estimated $897K.
  • TFS Capital first reported a position in Acorda Therapeutics in Q2 2013 and held it in 13 quarters.
  • TFS Capital's Acorda Therapeutics position peaked at $4.49M in Q4 2014.
  • 152 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2017.

Based on TFS Capital's 13F filing for Q3 2017.